ClinicalTrials.gg
RecruitingNCT05405868NAMinGUpdated May 9, 2024

Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial

A Phase 3 interventional study of Nicotinomide and Matching placebo in Glaucoma, Open-Angle, sponsored by University College, London. Recruiting at 10 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-09.

Sponsored by University College, London · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
496
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Glaucoma, Open-Angle with a site in United Kingdom — 5 open to participants now, 7 under way, 1 of them phase 3. Glaucoma, Open-Angle · United Kingdom.

Planned enrollment
8th of 26
496 · median 229
Started
2024
the only one that year
Phase 3
8 of 34
1 open now
Registered
30th of 34
by date

Among the 34 studies in Glaucoma, Open-Angle with a site in United Kingdom, this one is the 8th largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2024, is one of 8 in phase 3, and was the 30th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

5 of the 34 studies in Glaucoma, Open-Angle with a site in United Kingdom are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Glaucoma, Open-Angle with a site in United Kingdom, or all of them as a file.
02

Study summary

Glaucoma is the leading cause of sight impairment and blindness worldwide. It is a long-term eye disease which can cause permanent loss of sight and sometimes blindness and affects 1 in 50 people over 50 years of age. Open-angle glaucoma (OAG) is the most common type of glaucoma. This tends to develop slowly over many years, caused by the drainage pathway in the eye gradually becoming blocked over time due to a build-up of fluid. This build-up causes pressure in the eye to increase (intra-ocular pressure (IOP)), which then damages the important nerve at the back of the eye called the optic nerve, resulting in vision loss. Current treatments offered for glaucoma (eye drops or laser surgery), aim to lower eye pressure and have shown to slow vision loss, however, visual disability and blindness rates remain unacceptably high and many patients continue to lose vision despite these treatments, suggesting that the optic nerve in some patients is more easily damaged. Recent research has looked at cells called 'mitochondria'. These cells produce most of the energy in the body, and the nerve cells in the eye need a lot of energy to function and survive. Nicotinamide (NAM) is a form of Vitamin B3 and evidence so far has shown that mitochondrial function can be improved with this treatment. The aim of this trial is to find out whether taking oral NAM when used with current standard treatment for lowering pressure in the eye, can reduce the amount of sight loss in recently diagnosed patients with OAG, and evaluate the long-term safety and effectiveness of NAM. The trial will use two groups of people recently diagnosed with glaucoma and who have normal care (drops or laser) to lower eye pressure. Using a method of randomisation (randomly allocated to each group using a computer system), one group will be given NAM and the other group will be given a placebo or 'dummy pill'. This is a double masked trial meaning the participant nor the Investigator will be told which treatment group patients have been allocated to.

Read the detailed description

Open Angle Glaucoma (OAG) is a chronic optic neuropathy causing progressive vision loss. It is well established that IOP is the only currently modifiable risk factor for glaucoma progression, and it is widely accepted that other risk factors modulate the susceptibility of an eye to IOP. This has led to a considerable body of research into neurodegenerative mechanisms and potential neuroprotective approaches. Various pathways contributing to the neurodegeneration have been implicated, and many have focussed on the role of mitochondria. Neuroprotection would significantly reduce sight loss and the burden of IOP-lowering eye drop treatment needed for disease control. There is evidence that susceptibility to IOP is related to mitochondrial function and ageing is associated with mitochondrial functional decline. The knowledge gap addressed in this trial is the relative contribution that mitochondrial function makes to glaucomatous neurodegeneration and whether boosting mitochondrial function with NAM slows progression in humans in the same way that it does in animal models. Biomarkers for mitochondrial-related susceptibility have not yet been established in humans. The proposal therefore is a new mechanism neuroprotection to improve resistance to eye pressure and evaluate the long-term safety and efficacy of NAM to preserve vision and its mechanism of action. There is strong evidence that mitochondrial dysfunction is associated with OAG susceptibility and that NAM improves mitochondrial function. Research has shown short-term vision improvement with high-dose NAM in glaucoma patients. NAM is safe and well-tolerated.

03

Conditions studied

  • Glaucoma, Open-Angle

Browse trials for

Keywords

  • Nicotinamide
  • Vitamin B3
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who have been recently diagnosed (within the last 12 months) with early to moderate open-angle glaucoma (OAG) in at least one eye (including primary OAG, normal tension glaucoma (NTG) and pseudoexfoliation glaucoma)
  2. Open angle on gonioscopy
  3. Adults aged 18 years or over
  4. Snellen visual acuity 6/12 or better in at least one eye meeting the visual field (VF) criteria
  5. Visual Field (VF) mean deviation (MD) no worse than -12dB in either eye
  6. A negative pregnancy test result at the screening and baseline visit prior to randomisation for women of
  7. Ability to provide to participate
  8. Able and willing to attend trial visits and comply with trial procedures for the duration of the trial

Exclusion criteria

Exclusion Criteria:

  1. Pigment dispersion glaucoma
  2. Pregnancy (or planned pregnancy during the trial) and/or breastfeeding
  3. Women of and male participants with a partner of childbearing potential not willing to use highly effective for the duration of the trial treatment and for the time period specified following last trial treatment administration.
  4. Current treatment with either isoniazid, pyrazinamide, carbamazepine, phenobarbital or primidone
  5. Current liver disease or laboratory results with elevated levels of liver transaminases ( or ALT >3 x ) at screening visit.
  6. Renal failure ( \<30mL/min/1.73m²) at screening visit.
  7. Conditions affecting both eyes which may affect the Visual Field test result:

    1. Diabetic retinopathy or any other retinal disease causing VF loss
    2. cataract (likely to require cataract surgery within the next 2 years)
    3. Dementia or other non-glaucomatous neurological disease causing VF loss
    4. Adnexal conditions causing VF loss (including but not limited to blepharochalasis)
  8. Diagnosed with cancer in the last 5 years (with exception of non-melanoma skin cancer).
  9. Any clinical condition that, in the investigator's opinion would make the participant unsuitable for the trial.
  10. Concurrently enrolled in any other interventional trial or participation in previous clinical trial of glaucoma.
  11. Current use of, and unwilling to abstain from, over-the-counter additional vitamin B3/NAM oral supplements (including skin preparations such as ointments/emulsions), Ginkgo Biloba and/or Coenzyme Q10 supplements, throughout the duration of their participation in the trial.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
496 participants (estimated)

Study arms

  • Experimental
    Nicotinamide

    Participants will receive Nicotinamide for up to 27 months (treatment period) in addition to an initial treatment of Standard of Care IOP- lowering therapy (prior to randomisation and start of trial treatment) . They will receive 1.5g/day for the first 6 weeks, then dose increase to 3.0g/day for remainder of the treatment period.

    Drug: Nicotinomide

  • Placebo comparator
    Matching Placebo

    Participants will receive matching placebo for up to 27 months (treatment period) in addition to an initial treatment of Standard of Care IOP- lowering therapy (prior to randomisation and start of trial treatment) . They will receive 1.5g/day for the first 6 weeks, then dose increase to 3.0g/day for remainder of the treatment period.

    Drug: Matching placebo

Interventions

  • DrugNicotinomide

    Nicotinamide tablets (750mg)

  • DrugMatching placebo

    Matching placebo

06

What researchers measure

Primary outcomes

  1. The difference between the treatment arms in change of Visual Field (VF) mean deviation (MD) at 27 months measured by the Humphrey Visual Field Analyser test

    The Humphrey Visual Field Analyser test is a diagnostic tool commonly used to assess the retina's ability to detect a light stimulus at specific points within the visual field, called retinal sensitivity. Participants will undergo visual field testing at Screening, Baseline, Months 3, 6,12,18, 24 and Month 27 using the Humphrey Visual Field analyser with the SITA Standard 24-2 programme. The results will be used to measure the progression of vision loss between the active arm (Nicotinamide) and the comparator (matching placebo) The primary endpoint will be analysed using a linear mixed model to estimate the difference between treatment groups in VF MD at 27 months. The model will include month 27 VF MD as the outcome and baseline VF MD, IOP-lowering treatment type (eye drops vs laser) and baseline serum NAM levels as covariates.

    Time frame: Month 27; end of trial treatment

Secondary outcomes

  1. The difference in Visual Field (VF) mean deviation (MD) at 3 months (0-3 months - neuro-recovery) between the active treatment group and the placebo group, measured using the Humphrey Visual Field analyser test with the SITA Standard 24-2 programme

    The Humphrey Visual Field Analyser test is a diagnostic tool commonly used to assess the retina's ability to detect a light stimulus at specific points within the visual field, called retinal sensitivity. Participants will undergo visual field testing using the Humphrey Visual Field analyser with the SITA Standard 24-2 programme. The results will be used to measure the progression of vision loss between the active arm (Nicotinamide) and the comparator (matching placebo) over the initial 0-3 months

    Time frame: From Baseline until Month 3

  2. Quality-of-Life outcome differences between the two treatment groups at baseline, month 3 and month 27, as measured by the descriptive system for health-related quality of life, EQ-5D-5L with additional vision specific questions.

    The EQ-5D-5L (with vision bolt-on) is a participant self-reported questionnaire which evaluates the generic quality of life at the time of completion. It comprises of one question for each of the five dimensions; no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. A Visual Analogue Scale is also used and is a scale measured from 0 -100 scale where patients are asked to indicate their overall health on the day of questionnaire completion. This version of the questionnaire will also include additional vision related questions as part of the 5 dimensions, known as vision bolt on questions.

    Time frame: At Baseline, Month 3 and Month 27

  3. Quality-of-Life outcome differences between the two treatment groups at baseline, month 3 and month 27, as measured by the 15-item Glaucoma Quality of Life Questionnaire.

    The Glaucoma Quality of Life Questionnaire (GQL-15) is a 15-item which measures the severity of visual disability and comprises of 15 vision-related items. The item-level responses for each factor are coded on a five-point scale (1 meaning no difficulty and 5 meaning severe difficulty), while 0 is marked if the participant does not perform the activity as a result of non-visual cause. These items are grouped into four subscales: 1) "Central and near vision" (two items); 2) "Peripheral vision" (six items); 3) "Dark adaptation and glare" (six items); and 4) "Outdoor mobility" (one item). Total score is derived by summing all item-level response scores.

    Time frame: At Baseline, Month 3 and Month 27

  4. The safety profile of high dose NAM, measured by liver function tests (LFTs) at Screening, Month 3 and Month 18

    The Liver Function test is a standard diagnostic laboratory assay used to diagnose and monitor liver disease or damage. The tests measure the levels of certain enzymes and proteins in the blood.

    Time frame: At Screening, Month 3 and Month 18

  5. The safety profile of high dose NAM, measured from blood glucose test, HbA1c at Screening, Month 3 and Month 18

    The HbA1c blood test is a standard diagnostic laboratory test used to measure blood sugar levels.

    Time frame: At Screening, Month 3 and Month 18

  6. The safety profile of high dose NAM, measured by estimated glomerular filtration rate (eGFR) at Screening, Month 3 and Month 18

    The eGFR blood test is a standard diagnostic laboratory test used to measure how well the kidney function is.

    Time frame: At Screening, Month 3 and Month 18

  7. The number of adverse events as assessed by CTCAE v5.0 from baseline to month 27

    Number of participants with treatment related adverse events assessed by CTCAE v5.0 from baseline to month 27.

    Time frame: From Baseline until end of trial treatment and trial completion at Month 27

Other outcomes

  1. The impact of NAM treatment on mitochondrial function in the active treatment group between baseline and month 27, measured using the Seahorse mitochondrial function test.

    The Seahorse mitochondrial function test measures oxygen during energy production processes that occur in the mitochondria by directly measuring the oxygen consumption rate (OCR) of cells. The measurement will be performed on Peripheral Blood Mononuclear Cell (PBMC) blood samples. NAM, which is a form of Vitamin B3 is crucial for cell metabolism, normal functioning of the central nervous system and the formation of red blood cells.

    Time frame: From Baseline until end of trial treatment at Month 27

  2. The impact of NAM treatment on mitochondrial function in the placebo group between baseline and month 27, measured using the Seahorse mitochondrial function test.

    The Seahorse mitochondrial function test measures oxygen during energy production processes that occur in the mitochondria by directly measuring the oxygen consumption rate (OCR) of cells. The measurement will be performed on Peripheral Blood Mononuclear Cell (PBMC) blood samples. NAM, which is a form of Vitamin B3 is crucial for cell metabolism, normal functioning of the central nervous system and the formation of red blood cells.

    Time frame: From Baseline until end of trial treatment at Month 27

  3. The association between lymphocyte mitochondrial function, measured by the Seahorse mitochondrial function test, and rate of visual field loss in the placebo group between baseline and month 27.

    The Seahorse mitochondrial function test measures oxygen during energy production processes that occur in the mitochondria by directly measuring the oxygen consumption rate (OCR) of cells. The measurement will be performed on Peripheral Blood Mononuclear Cell (PBMC) blood samples. Mitochondrial function will be regarded as time-varying covariate and a repeated measures model will be used.

    Time frame: From Baseline until end of trial treatment at Month 27

  4. The association between nicotinamide adenine dinucleotide levels, from peripheral blood mononuclear cells, and the rate of visual field loss in the placebo group between baseline and month 27.

    Nicotinamide (NAM) is a major precursor of nicotinamide adenine dinucleotide (NAD) in neurones. NAD is an essential cofactor in oxidative phosphorylation and adenosine triphosphate (ATP) production. It plays a central role in mitochondrial function. Peripheral blood mononuclear cell (PBMC) are used to measure immunological functions and will be used to measure NAD. Cells are isolated from blood samples using standardised density gradient technique (Ficoll-Paque). Mitochondrial function will be regarded as time-varying covariate and a repeated measures model will be used.

    Time frame: From Baseline until end of trial treatment at Month 27

  5. Test the hypothesis that lower mitochondrial function, measured using the Seahorse mitochondrial function test, is associated with lower nicotinamide (NAM) levels collected from vitamin B3 blood samples in the placebo group at baseline

    The Seahorse mitochondrial function test measures oxygen during energy production processes that occur in the mitochondria by directly measuring the oxygen consumption rate (OCR) of cells. The measurement will be performed on Peripheral Blood Mononuclear Cell (PBMC) blood samples. NAM levels is the measure of Vitamin B3, which is crucial for cell metabolism, normal functioning of the central nervous system and the formation of red blood cells. The vitamin B3 blood test is a standard diagnostic laboratory test used to measures the level of vitamin B3 in the blood and to determine Vitamin B3 (Niacin) deficiencies.

    Time frame: Baseline only

  6. Test the hypothesis that lower mitochondrial function, measured using the Seahorse mitochondrial function test, is associated with lower nicotinamide (NAM) levels collected from vitamin B3 blood samples in the active treatment group at baseline

    The Seahorse mitochondrial function test measures oxygen during energy production processes that occur in the mitochondria by directly measuring the oxygen consumption rate (OCR) of cells. The measurement will be performed on Peripheral Blood Mononuclear Cell (PBMC) blood samples. NAM levels is the measure of Vitamin B3, which is crucial for cell metabolism, normal functioning of the central nervous system and the formation of red blood cells. The vitamin B3 blood test is a standard diagnostic laboratory test used to measures the level of vitamin B3 in the blood and to determine Vitamin B3 (Niacin) deficiencies.

    Time frame: Baseline only

  7. Test hypothesis that lower mitochondrial function, measured by the Seahorse mitochondrial function test, is associated with lower nicotinamide adenine dinucleotide levels collected from peripheral blood mononuclear cells in the placebo group at baseline

    Nicotinamide (NAM) is a major precursor of nicotinamide adenine dinucleotide (NAD) in neurones. NAD is an essential cofactor in oxidative phosphorylation and adenosine triphosphate (ATP) production. It plays a central role in mitochondrial function. Low levels of NAD are associated with low levels of mitochondrial function. Peripheral blood mononuclear cell (PBMC) are used to measure immunological functions and will be used to measure NAD. Cells are isolated from blood samples using standardised density gradient technique (Ficoll-Paque).

    Time frame: Baseline only

  8. Test hypothesis that lower mitochondrial function, measured by the Seahorse mitochondrial function test, is associated with lower nicotinamide adenine dinucleotide levels collected from PBMC blood samples in the active treatment group at baseline

    Nicotinamide (NAM) is a major precursor of nicotinamide adenine dinucleotide (NAD) in neurones. NAD is an essential cofactor in oxidative phosphorylation and adenosine triphosphate (ATP) production. It plays a central role in mitochondrial function. Low levels of NAD are associated with low levels of mitochondrial function. Peripheral blood mononuclear cell (PBMC) are used to measure immunological functions and will be used to measure NAD. Cells are isolated from blood samples using standardised density gradient technique (Ficoll-Paque).

    Time frame: Baseline only

  9. Test the hypothesis that lower mitochondrial function, measured using the Seahorse mitochondrial function test, is associated with higher oxidised glutathione levels collected from peripheral blood mononuclear cells in the placebo group at baseline

    Glutathione is an antioxidant produced in cells and any imbalance can cause oxidative stress. High oxidative stress levels can be a precursor to disease and it is associated with lower mitochondrial function. Peripheral blood mononuclear cell (PBMC) are used to measure immunological functions and will be used to measure glutathione. Cells are isolated from blood samples using standardised density gradient technique (Ficoll-Paque).

    Time frame: Baseline only

  10. Test hypothesis that lower mitochondrial function, measured using the Seahorse mitochondrial function test, is associated with higher oxidised glutathione levels collected from PBMC blood samples in the active treatment group at baseline

    Glutathione is an antioxidant produced in cells and any imbalance can cause oxidative stress. High oxidative stress levels can be a precursor to disease and it is associated with lower mitochondrial function. Peripheral blood mononuclear cell (PBMC) are used to measure immunological functions and will be used to measure glutathione. Cells are isolated from blood samples using standardised density gradient technique (Ficoll-Paque).

    Time frame: Baseline only

  11. The connection between nicotinamide (NAM) levels, measured from vitamin B3 blood samples, and the EPIC Food Frequency Questionnaire responses in the placebo group at baseline

    The EPIC Food Frequency Questionnaire (FFQ) is to measure a participant's usual food intake during the previous year and will help identify the intake level and absorption of Vitamin B3 via natural sources of food. NAM levels is the measure of Vitamin B3, which is crucial for cell metabolism, normal functioning of the central nervous system and the formation of red blood cells. The vitamin B3 blood test is a standard diagnostic laboratory test used to measures the level of vitamin B3 in the blood and to determine Vitamin B3 (Niacin) deficiencies.

    Time frame: Baseline only

  12. The connection between nicotinamide (NAM) levels, measured from vitamin B3 blood samples, and the EPIC Food Frequency Questionnaire responses in the active treatment group at baseline

    The EPIC Food Frequency Questionnaire (FFQ) is to measure a participant's usual food intake during the previous year and will help identify the intake level and absorption of Vitamin B3 via natural sources of food. NAM levels is the measure of Vitamin B3, which is crucial for cell metabolism, normal functioning of the central nervous system and the formation of red blood cells. The vitamin B3 blood test is a standard diagnostic laboratory test used to measures the level of vitamin B3 in the blood and to determine Vitamin B3 (Niacin) deficiencies.

    Time frame: Baseline only

  13. The connection between NAD levels, measured from peripheral blood mononuclear cells, and the EPIC Food Frequency Questionnaire responses in the placebo group at baseline

    The EPIC Food Frequency Questionnaire (FFQ) is to measure a participant's usual food intake during the previous year and will help identify the intake level and absorption of Vitamin B3 via natural sources of food. Peripheral blood mononuclear cell (PBMC) are used to measure immunological functions and will be used to measure NAD. Cells are isolated from blood samples using standardised density gradient technique (Ficoll-Paque).

    Time frame: Baseline only

  14. The connection between NAD levels, measured from peripheral blood mononuclear cells, and the EPIC Food Frequency Questionnaire responses in the active treatment group at baseline

    The EPIC Food Frequency Questionnaire (FFQ) is to measure a participant's usual food intake during the previous year and will help identify the intake level and absorption of Vitamin B3 via natural sources of food. Peripheral blood mononuclear cell (PBMC) are used to measure immunological functions and will be used to measure NAD. Cells are isolated from blood samples using standardised density gradient technique (Ficoll-Paque).

    Time frame: Baseline only

  15. The connection between oxygen consumption rate (OCR) levels, measured from peripheral blood mononuclear cells, and the EPIC Food Frequency Questionnaire responses in the placebo group at baseline

    The EPIC Food Frequency Questionnaire (FFQ) is to measure a participant's usual food intake during the previous year and will help identify the intake level and absorption of Vitamin B3 via natural sources of food. Peripheral blood mononuclear cell (PBMC) are used to measure immunological functions and will be used to measure OCR. Cells are isolated from blood samples using standardised density gradient technique (Ficoll-Paque).

    Time frame: Baseline only

  16. The connection between oxygen consumption rate (OCR) levels, measured from peripheral blood mononuclear cells, and the EPIC Food Frequency Questionnaire responses in the active treatment group at baseline

    The EPIC Food Frequency Questionnaire (FFQ) is to measure a participant's usual food intake during the previous year and will help identify the intake level and absorption of Vitamin B3 via natural sources of food. Peripheral blood mononuclear cell (PBMC) are used to measure immunological functions and will be used to measure OCR. Cells are isolated from blood samples using standardised density gradient technique (Ficoll-Paque).

    Time frame: Baseline only

  17. The effect of NAM on the rate of visual field loss between Month 3 and Month 27,measured by the Humphrey Visual Field Analyser test

    The Humphrey Visual Field Analyser test is a diagnostic tool commonly used to assess the retina's ability to detect a light stimulus at specific points within the visual field, called retinal sensitivity.

    Time frame: From Month 3 until end of trial treatment at Month 27

  18. The effect of NAM on the level of mitochondrial function in participants with low vs high baseline mitochondrial function and low vs high baseline NAM levels between month 3 and month 27, measured from Vitamin B3 blood samples .

    The Vitamin B3 is crucial for cell metabolism, normal functioning of the central nervous system and the formation of red blood cells. The vitamin B3 blood test is a standard diagnostic laboratory test used to measures the level of vitamin B3 in the blood and to determine Vitamin B3 (Niacin) deficiencies.

    Time frame: From Baseline until end of trial treatment at Month 27

  19. The association between lymphocyte mitochondrial function, measured by the Seahorse mitochondrial function test, and quality of life measures, as measured by the EQ-5D-5L and GQL-15 questionnaires, in the placebo group between baseline and month 27.

    The Seahorse mitochondrial function test measures oxygen during energy production processes that occur in the mitochondria by directly measuring the oxygen consumption rate (OCR) of cells. The measurement will be performed on Peripheral Blood Mononuclear Cell (PBMC) blood samples.

    Time frame: From Baseline until end of trial treatment at Month 27

  20. The association between lymphocyte mitochondrial function, measured by the Seahorse mitochondrial function test, and quality of life measures, measured by the EQ-5D-5L and GQL-15, in the active treatment group between baseline and month 27.

    The Seahorse mitochondrial function test measures oxygen during energy production processes that occur in the mitochondria by directly measuring the oxygen consumption rate (OCR) of cells. The measurement will be performed on Peripheral Blood Mononuclear Cell (PBMC) blood samples.

    Time frame: From Baseline until end of trial treatment at Month 27

  21. The association between baseline NAM levels and rate of visual field loss in the placebo group between baseline and month 27, as measured by the Humphrey Visual Field Analyser test and Vitamin B3 blood samples.

    The Humphrey Visual Field Analyser test is a diagnostic tool commonly used to assess the retina's ability to detect a light stimulus at specific points within the visual field, called retinal sensitivity. The Vitamin B3 is crucial for cell metabolism, normal functioning of the central nervous system and the formation of red blood cells. The vitamin B3 blood test is a standard diagnostic laboratory test used to measures the level of vitamin B3 in the blood and to determine Vitamin B3 (Niacin) deficiencies.

    Time frame: From Baseline until end of trial treatment at Month 27

  22. The association between NAM dosing and IOP in the active and placebo groups between baseline and month 27, measured by applanation tonometers .

    Intraocular pressure (IOP) is the fluid pressure inside the eye. Tonometry is the method used to determine the fluid pressure inside the eye (Intraocular pressure (IOP)) in the evaluation of patients at risk of glaucoma. Most tonometers are calibrated to measure pressure in millimeters of mercury (mmHg).

    Time frame: From Baseline until end of trial treatment Month 27

07

Study locations

4 of 10 sites recruiting
  • Belfast City Hospital
    Belfast, Northern Ireland BT9 7AB, United Kingdom
    Not yet recruiting
    • Augusto Azuara-Blanco · Principal investigator
  • Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust
    Cambridge, CB2 OQQ, United Kingdom
    Not yet recruiting
    • Rupert Bourne · Principal investigator
  • Queen Victoria Hospital NHS Foundation Trust
    East Grinstead, RH19 3DZ, United Kingdom
    Recruiting
    • Gokulan Ratnarajan · Principal investigator
  • Royal Liverpool Hospital
    Liverpool, L7 8XP, United Kingdom
    Not yet recruiting
    • Neeru Vallabh · Principal investigator
  • Moorfields Eye Hospital NHS Foundation Trust
    London, EC1V 2PD, United Kingdom
    Recruiting
    • David Garway-Heath · Principal investigator
  • Barnet Hospital, Royal Free London NHS Foundation Trust
    London, EN5 3DJ, United Kingdom
    Not yet recruiting
    • Ameet Shah · Principal investigator
  • King's College Hospital NHS Foundation Trust
    London, SE5 9RS, United Kingdom
    Recruiting
    • Gerassimos Lascaratos · Principal investigator
  • Manchester Royal Eye Hospital
    Manchester, M13 9WL, United Kingdom
    Not yet recruiting
    • Jonathan Yu · Principal investigator
  • Nottingham University Hospitals NHS Trust
    Nottingham, NG7 2UH, United Kingdom
    Not yet recruiting
    • Anthony King · Principal investigator
  • Queen Alexandra Hospital
    Portsmouth, PO6 3LY, United Kingdom
    Recruiting
    • James Kirwan · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — No plan to share IPD has been made at this time

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Apr 2027, 39 months after the start.

Of 49 phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 39 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2022
First posted
Jun 6, 2022
StartActual
Jan 18, 2024
Primary completionEst.
Apr 30, 2027
CompletionEst.
Jun 30, 2027
Last update
May 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05405868
Collaborators
National Institute for Health Research, United Kingdom
Responsible party
Sponsor
First posted
Jun 6, 2022
Start date
Jan 18, 2024
Primary completion
Apr 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
May 9, 2024

Study contacts

NAMinG Trial Team
Contact
cctu.naming@ucl.ac.uk
0203 108 6148
Felicia Ikeji
Contact
f.ikeji@ucl.ac.uk
020 7679 9506
David Garway-Heath
principal investigator · UCL

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion